Is ruxolitinib ointment included in medical insurance when it is launched in China?

Ruxolitinib ointment (Opzelura) is a topical drug mainly used to treat skin diseases such as atopic dermatitis and non-segmental alopecia areata. Its core ingredient, ruxolitinib, is a selective Janus kinase (JAK) 1/2 inhibitor that can effectively reduce inflammatory reactions and improve skin symptoms by inhibiting the JAK-STAT signaling pathway. Due to its significant clinical efficacy, ruxolitinib ointment has received widespread attention in the international market.

As of2024, ruxolitinib ointment has not yet been officially launched in the Chinese market. This means that domestic patients currently cannot purchase the drug directly through local pharmacies, so they need to obtain the drug from abroad through overseas purchasing agents or the help of relatives and friends. In this case, the price of drugs is usually high, and the way to purchase drugs is not convenient enough, which brings certain challenges to patient treatment.

Regarding the issue of inclusion in medical insurance, ruxolitinib ointment has not yet been listed in the country, so it has not yet been included in China's medical insurance directory. Medical insurance coverage usually requires a certain period of evaluation of the drug after it is launched in the country, involving various factors such as the clinical effect of the drug, economic analysis, and market demand. Even if ruxolitinib ointment is launched in China in the future, it will still need to go through a certain approval process before it can be included in the national medical insurance directory and become an affordable treatment option for patients.

For patients who need ruxolitinib ointment, they can currently only obtain the drug through self-pay or overseas purchasing, which means that patients need to bear higher medical expenses. The price of original drugs abroad is usually as high as more than 10,000 yuan, while the price of more economical Bangladeshi generic drugs is about a few hundred yuan. Although the price is relatively low, it has not yet been included in China's medical insurance system. Therefore, patients should comprehensively consider the price of the drug, the way to purchase the drug, and the therapeutic effect when choosing a drug.

In the future, with the launch of ruxolitinib ointment in China and possible medical insurance coverage, patients' financial burden is expected to be reduced, and more patients will be able to obtain this highly effective treatment option.